Your Partner of Choice for Carbohydrates.

'a complete solution from GMP laboratories to GMP manufacturing'

The construction of new GMP laboratories enables us to take programmes through discovery to early phase clinical trials supply. The combination of this facility and our synthesis expertise offers customers a unique service for drug development programmes to scale up to commercial manufacture. 

Following laboratory development, processes are scaled up in one of the two pilot plants [total working area of 188 m2 (≈2000 sq. ft)] up to the 600 L (≈160 US gallon) scale. Pilot Plant One is a dedicated intrinsically safe working area containing 600 L stainless steel and 150 L (≈40 gallon) glass-lined vessels and associated equipment. Pilot Plant Two specialises in water based processes especially in the area of high quality extracts from biomass.

The Pilot Plant team is closely integrated to both the laboratory and the production facility, so scaling up from one area and department to the next is seamless.

See www.nzp.co.nz for large-scale synthesis and other manufacturing capabilities.

  • Dextra successfully delivered a number of novel nucleoside, nucleotide and carbohydrate targets for our company in a long standing collaboration, involving highly challenging chemistry and purification and against impressive timelines. The productive and rapid discussions between Dextra’s chemistry, analytical and business development departments and with our company were instrumental towards the completion of the projects. The range of expertise demonstrated by Dextra scientists led to synthetic issues being resolved in a timely manner and their input was key towards the progress achieved at a high level of quality. Dextra possesses a number of highly talented, skilled and dedicated chemists as well as supportive leadership and we have greatly appreciated their contributions. We would thoroughly recommend Dextra to companies who require medicinal chemistry and process development.

    Dr Alistair Stewart, Director CMC , Idenix Pharmaceuticals
  • Galecto Biotech has been very pleased to work with Dextra on a complex carbohydrate chemistry project. Dextra provided excellent service through route scouting, process development and delivery of toxicology and GMP API batches. Communication is open and honest and Galecto Biotech gladly recommends Dextra as a collaboration partner.

    Anders Pederson, Chief Operating Officer , Galecto Biotech
  • DFI has been pleased with Dextra who are a professional and adaptable company with high quality labs and talented staff. The Dextra team were able to resolve a complex reaction impurity profile through complimentary HPLC and IC methods, which contributed to the understanding and scale-up of our process. Communication has always been open and honest through regular teleconferences, meeting and reports. We recommend Dextra as a company to work with for research intended for industrial projects.

    Jonathan Stapley, Chief Technology Officer , DFI Corporation

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site

EU Cookie Directive Information